Vivek Subbiah: Rare Disease Symposium, Indianapolis

Razelle Kurzrock reshared a post by Vivek Subbiah on X, adding:

“Really enjoyed meeting Dr Ruema Birhiray. Hope we can find ways to collaborate. And it was a pleasure connecting in person again with Vivek”

Quoting Vivek Subbiah’s post:

“Thank you to Dr. Ruemu Birhiray and Dr. Bhatia for inviting me to speak at the Rare Disease Symposium, Indianapolis, IN – “Rare Cancer Precision Medicine”.

Dr. Birhiray’s commitment to Diversity, Equity and Inclusion in oncology is inspiring as he spearheads many initiatives in the community. Incredible rockstar speaker line up Razelle Kurzrock at OncoAlert.”

Source: Razelle Kurzrock/X and Vivek Subbiah/X

Dr. Razelle Kurzrock is the Chief Medical Officer at ACT Genomics, Senior Deputy Director at the HKSH Cancer Centre, and Senior Advisor at CureScience. She is also a Professor of Medicine at the University of California, San Diego (UCSD) and the Director of the Center for Personalized Cancer Therapy at UCSD. Additionally, Dr. Kurzrock is the founding director of the Michels Rare Cancers Research Laboratories at the MCW Cancer Center. Renowned as one of the world’s top 25 voices in precision medicine, she is celebrated for her contributions, of having over 950 scientific and medical publications.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.